Palatal Wound Healing After Free Gingival Graft Harvest in Diabetic Patients: A Clinical Trial
Mauro Santamaria · NCT07500935
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 40
- US sites recruiting
- 1
- Study start
- September 9, 2026
- Record last updated
- October 22, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to evaluate local and systemic factors involved in palatal mucosal healing after Free Gingival Graft harvest in diabetic patients and to compare them with those in non-diabetic patients.
Diabetic and non-diabetic volunteers of both sexes aged ≥ 18 years with gingival recession may participate. The main questions it aims to answer are:
- If the palatal wound healing (area of the wound) and percentage of wound epithelialization are different in diabetics compared to non-diabetics.
- If different factors, such as the oral microbiome, inflammatory markers, and others, are associated with the clinical outcome.
Participants will be asked
- Receive the procedure to treat their gingival recession defects
- To attend follow-up visits at 7, 14, 30, and 90 days after treatment.
- To provide different biological samples
- To answer different questionnaires.
Being studied: Free gingival graft
Conditions: Diabetes Mellitus; Gingival Recession, Generalized; Gingival Recession, Localized
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- aged ≥ 18 years;
- non-diabetic and diabetic patients (HbA1c>7% (American Diabetes Association 2025) managed with oral hypoglycemic agents or insulin;
- in the need of gingival recession treatment (RT1) in upper or lower arches with identifiable or restored cement-enamel junction (CEJ);
- periodontal stable (BoP ≤25%)(Lang et al. 2003);
- no morphological or pathological conditions in the palatal mucosa.
Exclusion Criteria
- patients with cardiovascular, blood dyscrasias, and immunodeficiency that contraindicate surgical procedures;
- taking medications known to interfere with the wound healing process or that contraindicate the surgical procedure;
- Pregnancy/lactation (assessed via self-report);
- current opportunistic oral lesions that mainly colonize the palate region;
- subjects that have taken antibiotics within the last 3 months or need for antibiotic prophylaxis;
- prisoners;
- signs or symptoms of active extra-oral head and neck infection (swelling) as determined by a dentist at the time of evaluation;
- subjects who cannot read or speak English or Spanish, and do not agree to having the assistance of an interpreter
Recruiting US locations
College of Dentistry - University of Kentucky
Lexington, KY 40536
Site contact: Mauro Pedrine Santamaria, DDS, Ms, PhD · 859 323 6297 · maurosantamaria@uky.edu
Study contacts (from the official record)
- Dawn G Dawson · 8593235409 · dawn.dawson@uky.edu
Similar studies in Kentucky
All diabetes studies in Kentucky →- RecruitingHealthy volunteers
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Cleerly, Inc.
- Location
- Edgewood, KY + 121 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Lexington, KY + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
Boehringer Ingelheim
- Location
- Lexington, KY + 56 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Sanofi
- Location
- Louisville, KY + 33 other US sites
- Eligibility basics
- Ages 1–25